Business Context and Reporting Period
This Form 8-K Current Report was filed by Tango Therapeutics, Inc. (TNGX) on February 28, 2023, regarding events occurring on February 27, 2023. The filing discloses the appointment of Adam Crystal, M.D., Ph.D., as the Company's President, Research & Development, effective February 27, 2023. Dr. Crystal will oversee all phases of product development from discovery through clinical development.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes and Compensation Details
The primary material change is the new executive appointment and the associated compensatory arrangements outlined in the Employment Agreement:
- Base Salary: $550,000 annually.
- Sign-on Bonus: $275,000 (subject to full recovery if Dr. Crystal voluntarily leaves prior to February 27, 2024).
- Cash Incentive: Target bonus of 45% of annual base salary.
- Stock Options: 487,500 shares with an exercise price equal to the closing price on the Grant Date (March 1, 2023). Vesting schedule: 25% on February 27, 2024, and the remainder in 36 equal monthly installments.
- Restricted Stock Units (RSUs): 81,250 shares vesting over a 3-year schedule (approximately 27,084 shares in 2024, 27,083 in 2025, and 27,083 in 2026).
Outlook, Risks, and Termination Provisions
The filing details specific termination benefits and risks associated with the executive agreement:
- Termination without Cause/Good Reason: Entitles Dr. Crystal to 12 months of base salary continuation, unpaid cash bonuses, pro-rata bonus, and COBRA premium coverage for up to 12 months.
- Change in Control: If termination occurs within 12 months of a change in control, 100% of time-based stock options and awards will be accelerated.
- Regulatory Disclosure: The press release announcing this appointment is furnished under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the closing price of TNGX common stock on March 1, 2023, to determine the exercise price of the 487,500 stock options.
- Review the Company's 2023 Inducement Plan to confirm the authority for these equity grants.
- Monitor future filings for the actual grant date confirmation and any adjustments to the vesting schedule.
- Assess the impact of the $275,000 sign-on bonus on the Company's immediate cash burn rate.